Hi @Eqz, nice to hear from you & good to see you are still keeping tabs on things here, I miss your posts & be great to see you back when the timing is right for you.
I can’t answer your question on the Busselton Lung study, maybe one to ask the company? That study is very long running isn’t it.
Yes, dissapointing with these hold ups, but that’s life’s journey I guess & good things come to those who wait, things don’t always pan out in a straight line & I suspect the opportunity with Janssen collaboration has much to do with this but that’s just IMO & will take time.
The frustrating thing is the number of patients PromarkerD could be benefiting right now & making a difference to their lives, global health budgets & PIQ MC. Hopefully we receive some updates soon, news regarding the US patent was very encouraging especially regarding drug development.
Ann: Appendix 4C - December 2018 Quarterly Report, page-9
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
68.0¢ |
Change
-0.020(2.86%) |
Mkt cap ! $85.15M | |||
| Open | High | Low | Value | Volume |
| 70.0¢ | 70.0¢ | 67.0¢ | $24.61K | 36.19K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7250 | 67.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 68.0¢ | 10966 | 1 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| PIQ (ASX) Chart |
